리도카인 염산염 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the lidocaine hydrochloride market size is expected to grow from USD 701.29 million in 2025 to USD 739.57 million in 2026 and is forecast to reach USD 965.03 million by 2031 at 5.46% CAGR over 2026-2031.

This report Segments the Industry Into by Dosage Form (Creams, Patches, Injectables, and More), Application (Heart Arrhythmia, Dental Procedures, Epilepsy Management, and More), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Lidocaine Hydrochloride Market Trends and Insights

Rising Volume of Minimally Invasive & Elective Surgeries

Outpatient laparoscopic and endoscopic procedures increasingly rely on lidocaine for swift onset anesthesia that supports same-day discharge. Evidence shows that intravenous lidocaine reduces postoperative pain scores by 40% and lowers opioid consumption in abdominal surgery patients.Hospitals incorporate the drug into enhanced-recovery pathways to manage costs tied to extended admissions. As ambulatory surgical centers compete on throughput, demand for predictable analgesia augments the lidocaine hydrochloride market. Suppliers able to guarantee continuous injectable supply capture share in regions where elective surgery volumes rebound most rapidly following pandemic-related slowdowns.

Increasing Prevalence of Ventricular Arrhythmias

Cardiovascular disease burdens an aging demographic, elevating the clinical use of lidocaine as a class IB anti-arrhythmic. Emergency departments value its rapid onset and brief half-life for controlled rhythm stabilization, particularly during percutaneous coronary interventions. Updated protocols recommend lidocaine to mitigate arrhythmia-related complications in cardiac catheterization labs. Broader availability of advanced cardiac care in emerging economies further enlarges the drug's addressable patient pool.

Adverse CNS & Cardiovascular Toxicity Risks

The therapeutic window for lidocaine remains narrow, prompting regulators to monitor high-strength topical products marketed for cosmetic procedures. In March 2024 the FDA warned a manufacturer marketing unapproved 40% lidocaine creams, underscoring safety vigilance. Clinicians must screen for hepatic impairment and methemoglobinemia risk, which can limit dosing flexibility. These concerns moderate uptake in elective aesthetic settings where alternatives with wider margins of safety are gaining traction.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Adoption of Topical Lidocaine Patches for Neuropathic Pain
2. Rapid Expansion of Dental Procedures in Emerging Economies
3. Generic Price Erosion & Reimbursement Pressures

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The injectables sub-segment represented 42.28% of the lidocaine hydrochloride market size in 2025 owing to its indispensability in surgical and emergency settings. Supply shortages from incumbent producers such as Pfizer and Fresenius Kabi prolonged lead times, yet facilitated share gains for agile suppliers introducing ready-to-use vials early in 2024. A second growth engine stems from patches, which post a 7.33% CAGR through 2031 as physicians and patients gravitate to non-invasive regimens. The March 2025 generic approval slashed unit costs by 35% within three months in the United States, broadening payer coverage and accelerating uptake. Creams, gels, and the emerging class of thermoresponsive nanogels sustain demand in dermatology and oral-wound applications where extended release is advantageous. Nanotechnology-enhanced formats employing polymeric nanocapsules improve mucosal permeation and represent a future competitive differentiator for manufacturers seeking margin defense.

Hospital pharmacies still prioritize multidose ampoules for versatility, but ambulatory surgical centers increasingly order pre-filled syringes to minimize preparation time and medication errors. The lidocaine hydrochloride market maintains a strong pipeline of 3D-printed dissolvable microneedle arrays tailored for post-operative incision care. This personalized-delivery trend widens the innovation moat for technology-driven brands and mitigates pure price competition in the injectables space. At the same time, patches address adherence challenges in chronic neuropathic pain, presenting the most compelling opportunity for volume expansion across the lidocaine hydrochloride industry.

Complete Report Scope:

• By Dosage Form
  • Creams
  • Patches
  • Injectables
  • Gels
  • Aerosol Solutions
  • Other Dosage Forms
• By Application
  • Heart Arrhythmia
  • Dental Procedures
  • Epilepsy Management
  • Post-Herpetic Neuralgia
  • Cosmetic Dermatology
  • Other Applications
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained a 37.05% revenue share in 2025, underpinned by mature reimbursement systems and high elective-surgery volumes. The region also became the launchpad for the first generic 1.8% patch, which broadened access for Medicare and commercial-plan beneficiaries. United States drug-shortage data reveal recurring deficits in lidocaine vials, prompting hospital groups to diversify suppliers and renegotiate long-term contracts.

Europe follows with consistent demand driven by aging populations and harmonized regulatory pathways that expedite new-format approvals. German ambulatory centers reported a 12% rise in outpatient arthroscopic procedures in 2024, directly lifting lidocaine consumption. The lidocaine hydrochloride market size attributed to France and Italy shows resilient mid-single-digit growth as pain-management guidelines endorse topical routes before opioids.

Asia-Pacific delivers the highest 8.34% CAGR, reflecting broader insurance coverage and investment in domestic API capacity. India's Bulk Drug Parks scheme incentivizes local production of key intermediates to curb dependency on imports. China's biopharmaceutical sector benefits from provincial subsidies that lower facility-setup costs, enabling quick scale-up of lidocaine API manufacturing and reinforcing supply security for regional formulators.

Latin America experiences moderate expansion as Brazil and Mexico upgrade surgical infrastructure and dental-tourism inflows increase. Regulatory agencies are adopting fast-track reviews for critical anesthetics to avert shortages, a policy that favors established dossier holders. Middle East and Africa remain nascent but record double-digit volume gains where private hospital chains open day-surgery centers in urban hubs. Increasing public-sector procurement budgets for essential anesthetics establish a baseline demand that suppliers leverage for further penetration of premium topical formats.

1. Pfizer
2. Merck
3. Teva Pharmaceutical Industries
4. Amneal Pharmaceuticals
5. Endo International
6. Hikma Pharmaceuticals
7. Taro Pharmaceutical Industries Ltd.
8. Fresenius
9. Viatris
10. AstraZeneca
11. Johnson & Johnson
12. Amphastar Pharmaceuticals
13. Mahendra Chemicals
14. Nortec Quimica
15. Scilex Holding
16. Jiangsu Tianji Pharmaceutical Co., Ltd.
17. Sorrento Therapeutics
18. Shanghai Nianxing Industrial Co., Ltd.
19. Huons Co., Ltd.
20. Alembic Pharmaceuticals Ltd.
21. Dentsply Sirona
22. B. Braun

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Volume of Minimally-Invasive & Elective Surgeries
  • 4.2.2 Increasing Prevalence of Ventricular Arrhythmias
  • 4.2.3 Growing Adoption of Topical Lidocaine Patches for Neuropathic Pain
  • 4.2.4 Rapid Expansion of Dental Procedures in Emerging Economies
  • 4.2.5 FDA Approvals of Low-Dose High-Bioavailability Transdermal Systems
  • 4.2.6 3D-Printed Personalized Lidocaine Delivery Devices
• 4.3 Market Restraints
  • 4.3.1 Adverse CNS & Cardiovascular Toxicity Risks
  • 4.3.2 Generic Price Erosion & Reimbursement Pressures
  • 4.3.3 Volatility in Xylidine Raw-Material Supply
  • 4.3.4 Stricter Solvent-Emission Regulations in API Manufacturing
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Dosage Form
  • 5.1.1 Creams
  • 5.1.2 Patches
  • 5.1.3 Injectables
  • 5.1.4 Gels
  • 5.1.5 Aerosol Solutions
  • 5.1.6 Other Dosage Forms
• 5.2 By Application
  • 5.2.1 Heart Arrhythmia
  • 5.2.2 Dental Procedures
  • 5.2.3 Epilepsy Management
  • 5.2.4 Post-Herpetic Neuralgia
  • 5.2.5 Cosmetic Dermatology
  • 5.2.6 Other Applications
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Ambulatory Surgical Centers
  • 5.3.3 Specialty Clinics
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Pfizer Inc.
  • 6.3.2 Merck KGaA
  • 6.3.3 Teva Pharmaceutical Industries Ltd.
  • 6.3.4 Amneal Pharmaceuticals Inc.
  • 6.3.5 Endo International plc
  • 6.3.6 Hikma Pharmaceuticals PLC
  • 6.3.7 Taro Pharmaceutical Industries Ltd.
  • 6.3.8 Fresenius Kabi AG
  • 6.3.9 Viatris (Mylan N.V.)
  • 6.3.10 AstraZeneca plc
  • 6.3.11 Johnson & Johnson
  • 6.3.12 Amphastar Pharmaceuticals Inc.
  • 6.3.13 Mahendra Chemicals
  • 6.3.14 Nortec Quimica
  • 6.3.15 Scilex Holding Company
  • 6.3.16 Jiangsu Tianji Pharmaceutical Co., Ltd.
  • 6.3.17 Sorrento Therapeutics Inc.
  • 6.3.18 Shanghai Nianxing Industrial Co., Ltd.
  • 6.3.19 Huons Co., Ltd.
  • 6.3.20 Alembic Pharmaceuticals Ltd.
  • 6.3.21 Dentsply Sirona Inc.
  • 6.3.22 B. Braun Melsungen AG

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment